Johnson & Johnson Services INC
lobbying client · lobbying firm
Johnson & Johnson Services INC's federal footprint — reported lobbying spend and, where matched, federal money received. Figures are as reported to the U.S. Senate (LDA) and USAspending.
Reported country: 🇺🇸 United States
Lobbying over time
| FY | Lobbying spend (as client) | Lobbying billed / handled (as firm) |
|---|---|---|
| 2022 | $10,570,000 | $7,810,000 |
| 2023 | $10,340,000 | $6,850,000 |
| 2024 | $10,240,000 | $7,710,000 |
| 2025 | $11,050,000 | $8,360,000 |
Two figures: what Johnson & Johnson Services INC reported spending on its own lobbying (as a client) and what it billed or handled for the clients it represents (as a firm — revenue, not its own spend). For a self-filer these overlap.
Firms hired
- Brownstein Hyatt Farber Schreck, LLP $2,700,000 · 17 filings
- Fulcrum Public Affairs LLC $1,020,000 · 17 filings
- Cornerstone Government Affairs, INC. $960,000 · 16 filings
- Splitoak Strategies LLC $900,000 · 18 filings
- Navigators Global LLC (Formerly Dc Navigators, LLC) $840,000 · 16 filings
- The Nickles Group, LLC $830,000 · 18 filings
- Farragut Partners LLP $800,000 · 16 filings
- The Washington Tax & Public Policy Group $660,000 · 19 filings
- Todd Strategy Group $600,000 · 10 filings
- Ml Strategies, LLC $580,000 · 17 filings
Registrants that filed lobbying on behalf of Johnson & Johnson Services INC.
Clients represented
Self-filed — Johnson & Johnson Services INC registers and lobbies on its own behalf, with no separate outside clients.
Issues
| Issue area | Lobbied | Worked |
|---|---|---|
| Health Issues | 193 | 16 |
| Taxation/Internal Revenue Code | 84 | 16 |
| Medicare/Medicaid | 65 | 8 |
| Budget/Appropriations | 49 | 16 |
| Bankruptcy | 43 | 11 |
| Trade (domestic/foreign) | 24 | 13 |
| Torts | 19 | — |
| Civil Rights/Civil Liberties | 18 | 4 |
| Science/Technology | 16 | 16 |
| Consumer Issues/Safety/Products | 14 | 12 |
| Copyright/Patent/Trademark | 12 | 12 |
| Veterans | 12 | 12 |
| Environment/Superfund | 11 | 11 |
| Pharmacy | 11 | 11 |
| Labor Issues/Antitrust/Workplace | 8 | 8 |
| Law Enforcement/Crime/Criminal Justice | 8 | 7 |
| Government Issues | 3 | — |
| Tariff (miscellaneous tariff bills) | 3 | — |
| Medical/Disease Research/Clinical Labs | 1 | — |
Issue areas across Johnson & Johnson Services INC's filings, by activity count — as the client (Lobbied) and as the registrant/firm (Worked). Linked areas open the CivicGate issue page.
What they lobbied on
Reported activity from Senate LDA
-
FY2025 Health Issues as client
Issues such as infant & maternal mortality, global pandemics, climate change & sustainability.
-
FY2025 Taxation/Internal Revenue Code as client
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and the tax base of the U.S. and its Territories. Issues related to taxation of intellectual property income. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302) Issues related third party ligation financing (S. 1821, H.R. 1 - Section 70605).
H.R. 1990 S. 1639 H.R. 574 S. 187 H.R. 1062 H.R. 1347 S. 559 S. 1688 H.R. 1 S. 1821
-
FY2025 Health Issues as client
Educating members and staff on the company's presence in their districts and states and contributions to the wellbeing and health of their constituents.
-
FY2025 Health Issues as client
H.R. 1, One Big Beautiful Bill Act and pharmacy benefit management. Issues related to mental health. Issues related to SUPPORT Act Reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety.
-
FY2025 Medicare/Medicaid as client
Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1, One Big Beautiful Bill Act and issues related to drug pricing. Issues related to Most Favored Nation drug pricing. H.R. 946 / S. 1862, ORPHAN Cures Act.
-
FY2025 Taxation/Internal Revenue Code as client
H.R. 1, One Big Beautiful Bill Act, as it relates to corporate and international taxes.
-
FY2025 Bankruptcy as client
Issues related to litigation reform.
-
FY2025 Trade (domestic/foreign) as client
Monitor issues related to tariffs.
Show 52 more activities
-
FY2025 Health Issues self-filed
- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954, Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments
H.R. 1539 S. 266 H.R. 946 S. 864 H.R. 2214 H.R. 1492 S. 832 S. 1954 H.R. 2527 H.Res. 1301
-
FY2025 Budget/Appropriations self-filed
- Issues related to stroke care
-
FY2025 Copyright/Patent/Trademark self-filed
- S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions Issues related to - intellectual property, including S. 1040, a bill to amend the Federal Trade Commission Act to prohibit product hopping - Medication Affordability and Patent Integrity Act - patent thickets
-
FY2025 Law Enforcement/Crime/Criminal Justice self-filed
Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - the Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding
-
FY2025 Pharmacy self-filed
- Issues related to the SUPPORT Act
-
FY2025 Science/Technology self-filed
Issues related to - artificial intelligence - data privacy - cybersecurity - robotics
-
FY2025 Taxation/Internal Revenue Code self-filed
Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in TCJA including in 2025 reconciliation bills
-
FY2025 Veterans self-filed
- Issues related to Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology
-
FY2025 Budget/Appropriations as client
Issues related to appropriations, animal welfare, and health policy.
-
FY2025 Health Issues as client
Issues related to appropriations, animal welfare, and health policy.
-
FY2025 Health Issues as client
Issues related to cardiovascular health; H.R.5343 / S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025; issues related to Heart Recovery Awareness Day and H. Res. 1301, designating February 20th Heart Recovery Awareness Day
-
FY2025 Health Issues self-filed
- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act, regarding all provisions - S.1399 / H.R. 6167, the Health Tech Investment Act, regarding all provisions Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - MFN - Foreign Reference Pricing
H.R. 1539 H.R. 929 S. 266 H.R. 946 S. 864 H.R. 2214 H.R. 1492 S. 832 S. 1954 H.R. 5526 H.R. 2527 H.R. 5343 S. 1717 H.R. 4282 H.R. 4299 S. 1399 H.R. 6167 H.Res. 1301
-
FY2025 Budget/Appropriations self-filed
- Issues related to stroke care
-
FY2025 Copyright/Patent/Trademark self-filed
- S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions - H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act, regarding all provisions - S.2658, Medication Affordability and Patent Integrity Act Issues related to: - intellectual property - patent thickets - patent fees
-
FY2025 Law Enforcement/Crime/Criminal Justice self-filed
Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - H.R.2675, Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding
-
FY2025 Pharmacy self-filed
- Issues related to the SUPPORT Act
-
FY2025 Science/Technology self-filed
Issues related to - artificial intelligence - data privacy - cybersecurity - robotics
-
FY2025 Taxation/Internal Revenue Code self-filed
Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in OBBB and the corporate alternative minimum tax
-
FY2025 Veterans self-filed
Issues related to: - Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - VA Program - military/veterans affairs health workforce and talent workforce
-
FY2025 Trade (domestic/foreign) self-filed
- Issues related to USMCA review and renegotiation
-
FY2025 Medicare/Medicaid as client
Value of prescription drugs and patient access Issues related to Medicare Parts B & D P.L. 119-21 H.R. 946/S. 1862, ORPHAN Cures Act H.R. 2483, SUPPORT Act
-
FY2025 Law Enforcement/Crime/Criminal Justice as client
Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - the Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding
-
FY2025 Taxation/Internal Revenue Code as client
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302) Issues related third party ligation financing (S. 1821, H.R. 1 - Section 7060).
H.R. 1990 S. 1639 H.R. 574 S. 187 H.R. 1062 H.R. 1347 S. 559 S. 1688 H.R. 1 S. 1821
-
FY2025 Taxation/Internal Revenue Code as client
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302) Issues related third party ligation financing (S. 1821, H.R. 1 - Section 70605).
H.R. 1990 S. 1639 H.R. 574 S. 187 H.R. 1062 H.R. 1347 S. 559 S. 1688 H.R. 1 S. 1821
-
FY2025 Bankruptcy as client
Bankruptcy Law.
-
FY2025 Health Issues as client
Issues related to mental health. Issues related to SUPPORT Act Reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety.
-
FY2025 Medicare/Medicaid as client
Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. Issues related to Most Favored Nation drug pricing.
-
FY2025 Taxation/Internal Revenue Code as client
Monitor implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes.
-
FY2025 Bankruptcy as client
Issues related to litigation reform.
-
FY2025 Trade (domestic/foreign) as client
Issues related to tariffs.
-
FY2025 Health Issues as client
Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Monitored issues related to drug pricing. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025.
-
FY2025 Medicare/Medicaid as client
Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025.
-
FY2025 Taxation/Internal Revenue Code as client
H.R. 1990, the American Innovation and R&D Competitiveness Act, and issues related to the R&D tax credit. Issues related to the extension of the 2017 Tax Cut and Jobs Act provisions, and corporate and international taxes.
-
FY2025 Bankruptcy as client
Issues related to litigation reform.
-
FY2025 Medicare/Medicaid as client
Value of prescription drugs and patient access Issues related to Medicare Parts B & D P.L. 119-21 H.R. 946/S. 1862, ORPHAN Cures Act H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025/Public Law No: 119-44 Promoting U.S. competitiveness while ensuring U.S. leadership role in developing medicines
-
FY2025 Health Issues as client
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation.
-
FY2025 Taxation/Internal Revenue Code self-filed
Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in OBBB
-
FY2025 Veterans self-filed
Issues related to: - Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - VA Program
-
FY2025 Trade (domestic/foreign) self-filed
- Issues related to USMCA review and renegotiation
-
FY2025 Health Issues self-filed
- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act, regarding all provisions Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - MFN - Foreign Reference Pricing
H.R. 1539 H.R. 929 S. 266 H.R. 946 S. 864 H.R. 2214 H.R. 1492 S. 832 S. 1954 H.R. 5526 H.R. 2527 H.R. 5343 S. 1717 H.R. 4282 H.R. 4299 H.Res. 1301
-
FY2025 Budget/Appropriations self-filed
- Issues related to stroke care
-
FY2025 Copyright/Patent/Trademark self-filed
- S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions - H.R. 3269/S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act, regarding all provisions - S.2658, Medication Affordability and Patent Integrity Act Issues related to: - intellectual property, including S. 1040, a bill to amend the Federal Trade Commission Act to prohibit product hopping - patent thickets - patent fees
-
FY2025 Law Enforcement/Crime/Criminal Justice self-filed
Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - H.R.2675, Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding
-
FY2025 Pharmacy self-filed
- Issues related to the SUPPORT Act
-
FY2025 Science/Technology self-filed
Issues related to - artificial intelligence - data privacy - cybersecurity - robotics
-
FY2025 Health Issues as client
Issues relating to education on heart recovery as the standard of care, cardiovascular health, and diversity in cardiovascular clinical trials; issues relating medical device supply chains; issues related to Medicare coverage reform; issues related to health equity
-
FY2025 Health Issues as client
Issues related to public health, science and technology, sustainability, innovation, and competition.
-
FY2025 Civil Rights/Civil Liberties as client
Issues related to public health, science and technology, sustainability, innovation, and competition.
-
FY2025 Medicare/Medicaid as client
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
-
FY2025 Health Issues as client
Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation.
-
FY2025 Health Issues as client
Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing
-
FY2025 Taxation/Internal Revenue Code as client
Issues related to corporate and international tax Research and development costs H.R.1 One Big Beautiful Bill
The specific issues and bills Johnson & Johnson Services INC reported lobbying on, newest first. Bill references that CivicGate tracks link to the bill; others are shown as reported.